ArticleScience translational medicine2017
An oral microjet vaccination system elicits antibody production in rabbits.
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 68 citations in OpenAlex.
- Magnetically controlled delivery capsule endoscopy for precise drug delivery to intestinal lesions.Drug delivery and translational research · 2026Article
- Toward autonomous robotic-assisted and microrobotic surgery.Science advances · 2026Review
- Protein Delivery Using Three-Dimensional Printing of Buccal Films: Technological Advances and Clinical Potential.Pharmaceutics · 2026Review
- Combating respiratory diseases with mucosal vaccines.Journal of virology · 2026Review
- Microrobotic copper-rich electrochemical interfacing for targeted cancer theranostics in the gut.Science advances · 2026Article
- High-velocity delivery of biologics via the gastrointestinal tract by self-pressurized oral capsules.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Sublingual and Buccal Delivery: A Historical and Scientific Prescriptive.Pharmaceutics · 2025Review
- Article
- Development of 3D-Printed Two-Compartment Capsular Devices for Pulsatile Release of Peptide and Permeation Enhancer.Pharmaceutical research · 2024Article
- Robotic wireless capsule endoscopy: recent advances and upcoming technologies.Nature communications · 2024Review
- Article
- Foundations of gastrointestinal-based drug delivery and future developments.Nature reviews. Gastroenterology & hepatology · 2022Review
- Oral drug delivery for immunoengineering.Bioengineering & translational medicine · 2022Review
- Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease.Scientific reports · 2021Article
- Future Perspectives of Oral Delivery of Next Generation Therapies for Treatment of Skin Diseases.Pharmaceutics · 2021Review
- Bacteria-Based Microdevices for the Oral Delivery of Macromolecules.Pharmaceutics · 2021Review
- Oral delivery of proteins and peptides: Challenges, status quo and future perspectives.Acta pharmaceutica Sinica. B · 2021Review
- Application of 3D bioprinting in the prevention and the therapy for human diseases.Signal transduction and targeted therapy · 2021Review
- Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.Annual review of pharmacology and toxicology · 2021Review
- Engineering Antiviral Vaccines.ACS nano · 2020Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
Noninvasive immunization technologies have the potential to revolutionize global health by providing easy-to-administer vaccines at low cost, enabling mass immunizations during pandemics. Existing technologies such as transdermal microneedles are costly, deliver drugs slowly, and cannot generate mucosal immunity, which is important for optimal immunity against pathogens. We present a needle-free microjet immunization device termed MucoJet, which is a three-dimensional microelectromechanical systems-based drug delivery technology. MucoJet is administered orally, placed adjacent to the buccal tissue within the oral cavity, and uses a self-contained gas-generating chemical reaction within its two-compartment plastic housing to produce a high-pressure liquid jet of vaccine. We show that the vaccine jet ejected from the MucoJet device is capable of penetrating the buccal mucosal layer in silico, in porcine buccal tissue ex vivo, and in rabbits in vivo. Rabbits treated with ovalbumin by MucoJet delivery have antibody titers of anti-ovalbumin immunoglobulins G and A in blood serum and buccal tissue, respectively, that are three orders of magnitude higher than rabbits receiving free ovalbumin delivered topically by a dropper in the buccal region. MucoJet has the potential to accelerate the development of noninvasive oral vaccines, given its ability to elicit antibody production that is detectable locally in the buccal tissue and systemically via the circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.